Is HPV-DNA testing a useful tool in predicting low-grade squamous intraepithelial lesion outcome? A retrospective longitudinal study

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 1, 2010, Pages 317-326

  Zappacosta, R ^a   Caraceni, D ^b   Ciccocioppo, L ^b   Ottaviantonio, M ^b   Conti, F ^c   Andreozzi, S ^a   Petrucci, F ^a   Rosini, S ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Renzetti Hospital   (Italy)

^c Policlinico SS Annunziata   (Italy)

Author keywords

HPV DNA testing; Low grade cervical lesions; Prognostic markers

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DNA DETERMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; WART VIRUS;

EID: 77951756281     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300130     Document Type: Article

References (36)

1. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 2004; 128:1224-1229
2. International Agency for Research and Cancer. Human Papillomaviruses. In: IARC Monographs on the evaluation of carcinogenic risks to humans. Vol 90. IARC Monographs Press, ed. Lyon, 2007; p.33.
3. Rinaldi M, Iurescia S, Fioretti D, Ponzetto A, Carloni G. Strategies for successful vaccination against hepatocellular carcinoma. Int J Immunopathol Pharmacol 2009; 22:269-277
4. ALTS group. Human Papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesion: baseline data from a randomised trial. J Natl Cancer Inst 2000; 92:397-402.
5. Atkins KA, Jeronimo J, Stoler MH, et al. Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer 2006; 108:212-221 (Pubitemid 44835768)
6. Cuzich J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of Human Papillomavirus: the HART study. Lancet 2003; 362:1871-1876
7. Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting: intralaboratory and interlaboratory quality control in seven laboratories participating in the same clinical trial. Am J Clin Pathol 2005; 124:1-6.
8. Cuschieri KS, Graham C, Moore C, Cubie HA. Human Papillomavirus testing for the management of low-grade cervical abnormalities in the UK. Influence of age and testing strategy. J Clin Virol 2007; 38:14-18.
9. Ronco G, Cuzich J, Segnan N, et al: NTCC working group, HPV triage for low grade (LSIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007; 43:476-480
10. Rosini S, Zappacosta R, Di Bonaventura G, Caraceni D, Pilla D, Di Girolamo G, Esposito A, Piccolomini M, Piccolomini R. Management and triage of women in follow-up for low-grade cervical disease: association of HPV-DNA and RNA-based methods. Int J Immunopathol Pharmacol 2007; 20:341-347
11. Guyot A, Karim S, Kyi MS, Fox J. Evaluation of adjunctive HPV testing by Hybrid Capture II® in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infectious Diseases 2003; 3:23-29
12. Munoz N, Castellsague X, de Gonzalez AB, Gissman L. Chapter I: HPV in the etiology of human cancer. Vaccine 2006; 24:S1-S7.
13. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7:453-459
14. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopulos G, Dillner J. Chapter 9: clinical implications of HPV testing: a summary of mata-analyses. Vaccine 2006; 21:S78-S89.
15. Schiffman M, Wheeler C, Dasgupta A, Solomon D, Castle PE, for the ALTS Group. A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol 2005; 124:1-11.
16. Perrons C, Jelley R, Kleter B, Quint W, Brink N. Detection of persistent high risk human papillomavirus infection with Hybrid Capture II and specific SPF 10/LiPA. J Clin Virol 2005; 32:278-285
17. Sandri MT, lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche Amplicor Human Papillomavirus (HPV) test for detection of high-risk genotypes in cervical samples. J Clin Microbiol 2006; 44:2141-2146
18. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burk RD. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5b/GP6b primer systems. J Clin Microbiol 1997; 35:1304-1310
19. Snijders PJF, van der Brule AJC, Meijer CJLM. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201:1-6.
20. Rodriguez AC, Shiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513-517
21. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008; 110:S4-7.
22. Wright TC, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. NEJM 2003; 348:489-490
23. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293-299 (Pubitemid 32219816)
24. Tidy J. Forgotten implications of HPV positivity for the majority of females: a clinical perspective. Cytopathology 2002; 13:263-266
25. Cox TJ. HPV testing in patients' management: atypical squamous cells of undetermined significance and lowgrade squamous intraepithelial lesion. In: Emerging issues on HPV infections: from science to practice. 1st edition. J. Monsonego, ed. Karger. Paris, 2006; p. 120.
26. Castle PE, Cox JT, Jeronimo J, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol 2008; 111:847-856
27. Skomedal H, Kraus I, Silva I, et al. Direct detect of cervical carcinogenesis through mRNA. In: Emerging issues on HPV infections: from science to practice. 1st edition. J. Monsonego, ed. Karger. Paris, 2006; p. 82.
28. Boulet GAV, Horvath CAJ, Berghmans S, Bogersn J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomark Prev 2008; 17:810-817
29. Rodriguez R, Fadare O. Longitudinal cytological follow-up of patients with a Papanicolaou test interpretation of "atypical squamous cells of undetermined significance" that was followed by a negative reflex test for high-risk humanlomavirus types. Int J Gynecol Pathol 2008; 27:108-112
30. Nobbenhuis MA, Heimerhorst TJ, val der Brule AJ, et al. Cytologycal regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358:1782-1783
31. Kiviat NB, Hawes SE, Feng Q. Screening for cervical cancer in the era of HPV vaccine-the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst 2008; 100:290-291
32. New Technologies for Cervival Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9:937-945
33. Sherman ME, Lorincz AT, Scott DR, et al. Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis. JNCI 2003; 95:45-52.
34. Varnai AD, Bollmann M, Bankfalvi A, et al. Predictive testing of early cervical pre-cancer by detecting human Human Papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 2008; 19:457-465
35. Wenrzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007; 23:315-330
36. Franconi R, Massa S, Eliano E, Muller A, Cirilli A, Accardi L, Di Bonito P, Giorgi C, Venuti A. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV-16 E7 vaccine. Int J Immunopathol Pharmacol 2006; 19:187-197